What is FEMSelect?
FEMSelect specializes in the development and commercialization of EnPlace, an FDA-cleared, minimally invasive treatment designed specifically for women over 50 suffering from Pelvic Organ Prolapse. By prioritizing same-day treatment protocols, the company addresses a significant gap in the current healthcare landscape, offering a streamlined alternative to traditional surgical interventions. The firm operates at the intersection of medical device innovation and patient-centric care, providing comprehensive educational resources to both clinicians and patients to improve clinical outcomes and quality of life. Their market position is defined by a focus on high-impact, low-recovery procedures that align with the evolving demands of modern healthcare systems.
How much funding has FEMSelect raised?
FEMSelect has raised a total of $9M across 1 funding round:
Series B
$9M
Series B (2022): $9M with participation from New Age Ventures, Mid Atlantic Bio Angels, Robin Hood Ventures, Triventures, and MEDA Angels
Key Investors in FEMSelect
Triventures
A global venture capital fund that invests in early-stage companies with innovative breakthroughs in healthcare, focusing on bio-convergence and data-driven technologies.
MEDA Angels
A healthcare investment firm founded by physicians and scientists that leverages extensive industry networks to support innovative solutions for healthcare systems and payors.
Robin Hood Ventures
A leading angel investment group based in Philadelphia specializing in high-growth startups across the Life Sciences and Healthcare IT sectors.
What's next for FEMSelect?
With this recent infusion of capital, FEMSelect is well-positioned to accelerate its commercial growth strategy and deepen its penetration into the women's health market. The company is expected to leverage these funds to enhance its clinical training programs and expand its distribution network, ensuring that the EnPlace procedure becomes a standard of care for patients seeking effective, non-surgical options. Future strategic initiatives will likely focus on long-term clinical validation and the scaling of operational infrastructure to support increased demand, further solidifying the company's role as a leader in pelvic health innovation.
See full FEMSelect company page
